[{"orgOrder":0,"company":"Novacell","sponsor":"Ad Korea","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Heptameric peptide FPR2","moa":"G protein-coupled receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novacell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novacell \/ Ad Korea","highestDevelopmentStatusID":"4","companyTruncated":"Novacell \/ Ad Korea"}]

Find Infections and Infectious Diseases Clinical Drug Pipeline Developments & Deals by Novacell

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : The two companies will promote joint research and development to develop new drugs for the treatment of severe diseases of viral respiratory diseases, such as corona19, using the candidate NCP112.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Undisclosed

                          March 06, 2020

                          Lead Product(s) : Heptameric peptide FPR2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Ad Korea

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank